EEF2K and intracranial hemorrhage: On the other hand, treatment with the eEF2K non-specific activator rapamycin (2 μM) led to intracranial hemorrhage in wildtype larvae (Figure 6F; P < 0.05) and further aggravated the hemorrhagic defect of miR-132 morphants (Figure 6F; P < 0.001).